CRO MercachemSyncom snaps up Alcami site, boosting chemistry services

petri dishes in a lab
Financial details of MercachemSyncom's recent buy were not disclosed. (science photo/Shutterstock)

Midsized European drug discovery CRO MercachemSyncom has bought Netherlands-based Alcami’s European cGMP CMC drug substance development site, based in Weert.

The CDMO purchase, financials of which were not shared, allows the company to “expand our portfolio of chemistry services from compound design to clinical proof of concept,” Eelco Ebbers, MercachemSyncom CEO, said in a statement.

The deal sees MercachemSyncom now able to better scale up its clinical active pharmaceutical ingredient requirements alongside its site in Prague. “The long experience of the Weert team in designing and driving early clinical drug substance development programs will complement extensive process research capabilities based in Groningen and Nijmegen,” it said.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

Frank Leemhuis, M.D., managing director at MercachemSyncom, said: “With the addition of the Alcami Weert team, we have the perfect technical and cultural match. With modern, flexible plant capacity, we look forward to supporting many more clinical development programs for our customers.”

Suggested Articles

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.